Darusentan
- Generic Name
- Darusentan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22N2O6
- CAS Number
- 171714-84-4
- Unique Ingredient Identifier
- 33JD57L6RW
- Background
Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
- Indication
For the treatment of congestive heart failure and hypertension.
- Associated Conditions
- -
- Associated Therapies
- -
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 849
- Registration Number
- NCT00389779
- Locations
- ๐บ๐ธ
NEA Clinic, Jonesboro, Arkansas, United States
๐บ๐ธCardiovascular Research Inst. of Dallas, Dallas, Texas, United States
๐บ๐ธCentral Cardiology Medical Clinic, Bakersfield, California, United States
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 661
- Registration Number
- NCT00389675
- Locations
- ๐บ๐ธ
Arkansas Primary Care Clinic, PA, Little Rock, Arkansas, United States
๐บ๐ธMedical Investigators, Inc., Little Rock, Arkansas, United States
๐บ๐ธSt John's Center for Clinical Research, Jacksonville, Florida, United States
A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2007-01-18
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT00364026
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
- First Posted Date
- 2006-07-18
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 282
- Registration Number
- NCT00353574
- Locations
- ๐บ๐ธ
Apex Research Institute, Santa Ana, California, United States
๐บ๐ธCardiovascular Center of Sarasota, Sarasota, Florida, United States
๐บ๐ธCastlerock Clinical Research Consultants, Tulsa, Oklahoma, United States
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 352
- Registration Number
- NCT00330369
- Locations
- ๐บ๐ธ
CAMC Clinical Trials Center, Charleston, West Virginia, United States
๐บ๐ธInnovative Clinical Trials, San Antonio, Texas, United States
๐บ๐ธDeerfield Beach Cardiology Associates, Deerfield Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.